DISC MEDICINE INC. -

Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera

09 2 2024 08:00:00 提供 Nasdaq GlobeNewswire

Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer

07 2 2024 07:00:00 提供 Nasdaq GlobeNewswire

Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 1 2024 16:00:00 提供 Nasdaq GlobeNewswire

Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board

20 12 2023 15:30:00 提供 Nasdaq GlobeNewswire

Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting

11 12 2023 19:30:00 提供 Nasdaq GlobeNewswire

Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of Hematology (ASH) Annual Meeting

11 12 2023 11:00:00 提供 Nasdaq GlobeNewswire

Disc Medicine Announces Grant of US Patent for Methods of Treating Erythropoietic Protoporphyrias with Bitopertin

14 11 2023 15:44:17 提供 Nasdaq GlobeNewswire

Disc Medicine Reports Third Quarter 2023 Financial Results and Provides Business Update

09 11 2023 07:30:00 提供 Nasdaq GlobeNewswire

Disc Medicine to Participate in Upcoming Investor Conferences

08 11 2023 15:30:11 提供 Nasdaq GlobeNewswire

Disc Medicine Announces Multiple Presentations Across Portfolio at the 65th American Society of Hematology Annual Meeting and Key Program Updates

02 11 2023 08:00:00 提供 Nasdaq GlobeNewswire

Disc Medicine Announces Planned Departure of Chief Financial Officer Joanne Bryce

23 10 2023 08:15:00 提供 Nasdaq GlobeNewswire

Disc Medicine Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers

03 10 2023 07:30:00 提供 Nasdaq GlobeNewswire

Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera

20 9 2023 15:30:00 提供 Nasdaq GlobeNewswire

Disc Medicine to Participate in Upcoming Investor Conferences

30 8 2023 15:15:00 提供 Nasdaq GlobeNewswire

Disc Medicine Reports Second Quarter 2023 Financial Results and Provides Business Update

11 8 2023 07:00:00 提供 Nasdaq GlobeNewswire

Disc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia (DBA)

27 7 2023 08:00:01 提供 Nasdaq GlobeNewswire

Disc Medicine Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

22 6 2023 15:15:00 提供 Nasdaq GlobeNewswire

Disc Medicine Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

13 6 2023 21:39:30 提供 Nasdaq GlobeNewswire

Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

12 6 2023 15:00:00 提供 Nasdaq GlobeNewswire

Disc Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress

09 6 2023 06:00:00 提供 Nasdaq GlobeNewswire